BioXcel Therapeutics (BTAI) Expected to Announce Earnings on Thursday

BioXcel Therapeutics (NASDAQ:BTAI) is expected to release its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect BioXcel Therapeutics to post earnings of ($0.58) per share and revenue of $0.1520 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, March 27, 2026 at 9:30 AM ET.

BioXcel Therapeutics Stock Down 4.6%

NASDAQ BTAI opened at $1.65 on Thursday. The stock has a market capitalization of $36.09 million, a PE ratio of -0.17 and a beta of 0.18. The company has a 50 day moving average price of $1.68 and a two-hundred day moving average price of $2.09. BioXcel Therapeutics has a 12-month low of $1.17 and a 12-month high of $8.08.

Institutional Trading of BioXcel Therapeutics

Several large investors have recently modified their holdings of BTAI. Goldman Sachs Group Inc. acquired a new position in BioXcel Therapeutics in the 1st quarter valued at $50,000. Jane Street Group LLC acquired a new position in BioXcel Therapeutics during the 4th quarter worth $204,000. Geode Capital Management LLC lifted its position in BioXcel Therapeutics by 64.6% during the 4th quarter. Geode Capital Management LLC now owns 206,168 shares of the company’s stock worth $330,000 after acquiring an additional 80,928 shares during the last quarter. Millennium Management LLC boosted its holdings in BioXcel Therapeutics by 78.5% during the fourth quarter. Millennium Management LLC now owns 1,835,192 shares of the company’s stock valued at $2,936,000 after acquiring an additional 807,139 shares during the period. Finally, State Street Corp grew its position in shares of BioXcel Therapeutics by 19.9% in the fourth quarter. State Street Corp now owns 63,218 shares of the company’s stock valued at $101,000 after purchasing an additional 10,500 shares during the last quarter. 30.68% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of BioXcel Therapeutics in a report on Wednesday, January 21st. Rodman & Renshaw started coverage on shares of BioXcel Therapeutics in a report on Tuesday. They issued a “buy” rating and a $17.00 price objective for the company. HC Wainwright lowered their target price on shares of BioXcel Therapeutics from $10.00 to $6.00 and set a “buy” rating on the stock in a research report on Thursday, March 5th. Finally, Zacks Research upgraded BioXcel Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, March 9th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, BioXcel Therapeutics presently has an average rating of “Hold” and a consensus target price of $11.50.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes.

BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option.